161 related articles for article (PubMed ID: 31692290)
21. Germline Prolactin Receptor Mutation Is Not a Major Cause of Sporadic Prolactinoma in Humans.
Bernard V; Bouilly J; Beau I; Broutin I; Chanson P; Young J; Binart N
Neuroendocrinology; 2016; 103(6):738-45. PubMed ID: 26641246
[TBL] [Abstract][Full Text] [Related]
22. The SF3B1
Guo J; Li C; Fang Q; Liu Y; Wang D; Chen Y; Xie W; Zhang Y
J Exp Clin Cancer Res; 2022 Jan; 41(1):26. PubMed ID: 35039052
[TBL] [Abstract][Full Text] [Related]
23. Signaling pathways regulating pituitary lactotrope homeostasis and tumorigenesis.
Booth AK; Gutierrez-Hartmann A
Adv Exp Med Biol; 2015; 846():37-59. PubMed ID: 25472533
[TBL] [Abstract][Full Text] [Related]
24. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas.
Fusco A; Gunz G; Jaquet P; Dufour H; Germanetti AL; Culler MD; Barlier A; Saveanu A
Eur J Endocrinol; 2008 May; 158(5):595-603. PubMed ID: 18426817
[TBL] [Abstract][Full Text] [Related]
25. Heparin-binding secretory transforming gene (hst) facilitates rat lactotrope cell tumorigenesis and induces prolactin gene transcription.
Shimon I; Hüttner A; Said J; Spirina OM; Melmed S
J Clin Invest; 1996 Jan; 97(1):187-95. PubMed ID: 8550832
[TBL] [Abstract][Full Text] [Related]
26. Expression of estrogen receptor α and growth factors in human prolactinoma and its correlation with clinical features and gender.
Lv H; Li C; Gui S; Zhang Y
J Endocrinol Invest; 2012 Feb; 35(2):174-80. PubMed ID: 21422801
[TBL] [Abstract][Full Text] [Related]
27. Gene expression in prolactinomas: a systematic review.
Seltzer J; Scotton TC; Kang K; Zada G; Carmichael JD
Pituitary; 2016 Feb; 19(1):93-104. PubMed ID: 26238304
[TBL] [Abstract][Full Text] [Related]
28. The murine Pou6f2 gene is temporally and spatially regulated during kidney embryogenesis and its human homolog is overexpressed in a subset of Wilms tumors.
Di Renzo F; Doneda L; Menegola E; Sardella M; De Vecchi G; Collini P; Spreafico F; Fossati-Bellani F; Giavini E; Radice P; Perotti D
J Pediatr Hematol Oncol; 2006 Dec; 28(12):791-7. PubMed ID: 17164647
[TBL] [Abstract][Full Text] [Related]
29. Non-random trisomies of chromosomes 5, 8 and 12 in the prolactinoma sub-type of pituitary adenomas: conventional cytogenetics and interphase FISH study.
Finelli P; Giardino D; Rizzi N; Buiatiotis S; Virduci T; Franzin A; Losa M; Larizza L
Int J Cancer; 2000 May; 86(3):344-50. PubMed ID: 10760821
[TBL] [Abstract][Full Text] [Related]
30. microRNA expression profile and differentially-expressed genes in prolactinomas following bromocriptine treatment.
Wang C; Su Z; Sanai N; Xue X; Lu L; Chen Y; Wu J; Zheng W; Zhuge Q; Wu ZB
Oncol Rep; 2012 May; 27(5):1312-20. PubMed ID: 22366961
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas.
Ma W; Ikeda H; Yoshimoto T
Cancer; 2002 Jul; 95(2):258-66. PubMed ID: 12124824
[TBL] [Abstract][Full Text] [Related]
32. Expression of Stem Cell Markers and Dopamine D2 Receptors in Human and Rat Prolactinomas.
Gao Z; Cai L; Lu J; Wang C; Li Q; Chen J; Song X; Chen X; Zhang L; Zheng W; Su Z
Med Sci Monit; 2017 Apr; 23():1827-1833. PubMed ID: 28411401
[TBL] [Abstract][Full Text] [Related]
33. What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics.
Gürlek A; Karavitaki N; Ansorge O; Wass JA
Eur J Endocrinol; 2007 Feb; 156(2):143-53. PubMed ID: 17287403
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of Gs alpha mutations in Korean patients with pituitary adenomas.
Kim HJ; Kim MS; Park YJ; Kim SW; Park DJ; Park KS; Kim SY; Cho BY; Lee HK; Jung HW; Han DH; Lee HS; Chi JG
J Endocrinol; 2001 Feb; 168(2):221-6. PubMed ID: 11182759
[TBL] [Abstract][Full Text] [Related]
35. Clinical Case Seminar. Peculiar prolactinomas in patients with pituitary developmental gene mutations: from an adult endocrinologist perspective.
Doknic M; Pekic S; Civcic M; Popovic V
Hormones (Athens); 2012; 11(2):189-98. PubMed ID: 22801565
[TBL] [Abstract][Full Text] [Related]
36. mPRs represent a novel target for PRL inhibition in experimental prolactinomas.
Camilletti MA; Abeledo-Machado A; Perez PA; Faraoni EY; De Fino F; Rulli SB; Ferraris J; Pisera D; Gutierrez S; Thomas P; Díaz-Torga G
Endocr Relat Cancer; 2019 May; 26(5):497-510. PubMed ID: 30856609
[TBL] [Abstract][Full Text] [Related]
37. Cortistatin inhibits growth hormone release from human fetal and adenoma pituitary cells and prolactin secretion from cultured prolactinomas.
Rubinfeld H; Hadani M; Barkai G; Taylor JE; Culler MD; Shimon I
J Clin Endocrinol Metab; 2006 Jun; 91(6):2257-63. PubMed ID: 16595604
[TBL] [Abstract][Full Text] [Related]
38.
Cho HJ; Gurbuz F; Stamou M; Kotan LD; Farmer SM; Can S; Tompkins MF; Mammadova J; Altincik SA; Gokce C; Catli G; Bugrul F; Bartlett K; Turan I; Balasubramanian R; Yuksel B; Seminara SB; Wray S; Topaloglu AK
Front Endocrinol (Lausanne); 2023; 14():1203542. PubMed ID: 37600690
[TBL] [Abstract][Full Text] [Related]
39. MiR-137's Tumor Suppression on Prolactinomas by Targeting MITF and Modulating Wnt Signaling Pathway.
Lei C; Jing G; Jichao W; Xiaohui L; Fang Q; Hua G; Yazhou M; Zhang Y
J Clin Endocrinol Metab; 2019 Dec; 104(12):6391-6402. PubMed ID: 31162548
[TBL] [Abstract][Full Text] [Related]
40. [Differential expression analysis of prolactinoma-related microRNAs].
Chen YX; Li Q; Wang CD; Su ZP; Li WQ; Chen XB; Wu ZB
Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(5):320-3. PubMed ID: 22490835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
